M
Marc Lütgehetmann
Researcher at University of Hamburg
Publications - 255
Citations - 11548
Marc Lütgehetmann is an academic researcher from University of Hamburg. The author has contributed to research in topics: Medicine & Hepatitis B virus. The author has an hindex of 40, co-authored 188 publications receiving 7759 citations. Previous affiliations of Marc Lütgehetmann include American Board of Legal Medicine.
Papers
More filters
Journal ArticleDOI
Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study.
Dominic Wichmann,Jan-Peter Sperhake,Marc Lütgehetmann,Stefan Steurer,Carolin Edler,Axel Heinemann,Fabian Heinrich,Herbert Mushumba,Inga Kniep,Ann Sophie Schröder,Christoph Burdelski,Geraldine de Heer,Axel Nierhaus,Daniel Frings,Susanne Pfefferle,Heinrich Becker,Hanns Bredereke-Wiedling,Andreas de Weerth,Hans-Richard Paschen,Sara Sheikhzadeh-Eggers,Axel Stang,Stefan Schmiedel,Carsten Bokemeyer,Marylyn M. Addo,Martin Aepfelbacher,Klaus Püschel,Stefan Kluge +26 more
TL;DR: In this paper, the causes of COVID-19-related deaths were investigated in a single academic medical center in the German federal state of Hamburg for patients dying with a polymerase chain reaction-confirmed diagnosis of CoV-19 patients.
Journal ArticleDOI
Multiorgan and Renal Tropism of SARS-CoV-2.
Victor G. Puelles,Marc Lütgehetmann,Maja T. Lindenmeyer,Jan Sperhake,Milagros N. Wong,Lena Allweiss,Silvia Chilla,Axel Heinemann,Nicola Wanner,Shuya Liu,Fabian Braun,Shun Lu,Susanne Pfefferle,Ann Sophie Schröder,Carolin Edler,Oliver Gross,Markus Glatzel,Dominic Wichmann,Thorsten Wiech,Stefan Kluge,Klaus Pueschel,Martin Aepfelbacher,Tobias B. Huber +22 more
TL;DR: In this autopsy series, the authors found that SARS-CoV-2 has an organotropism beyond the respiratory tract, including the kidneys, heart, liver, and brai...
Journal ArticleDOI
Neuropathology of patients with COVID-19 in Germany: a post-mortem case series.
Jakob Matschke,Marc Lütgehetmann,Christian Hagel,Jan Sperhake,Ann Sophie Schröder,Carolin Edler,Herbert Mushumba,Antonia Fitzek,Lena Allweiss,Maura Dandri,Matthias Dottermusch,Axel Heinemann,Susanne Pfefferle,Marius Schwabenland,Daniel Sumner Magruder,Stefan Bonn,Stefan Bonn,Marco Prinz,Christian Gerloff,Klaus Püschel,Susanne Krasemann,Martin Aepfelbacher,Markus Glatzel +22 more
TL;DR: In general, neuropathological changes in patients with COVID-19 seem to be mild, with pronounced neuroinflammatory changes in the brainstem being the most common finding, and there was no evidence for CNS damage directly caused by SARS-CoV-2.
Journal ArticleDOI
Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B
Karsten Wursthorn,Marc Lütgehetmann,Maura Dandri,Tassilo Volz,Peter Buggisch,Bernhard Zöllner,Thomas Longerich,Peter Schirmacher,Frauke Metzler,Myrga Zankel,C. Fischer,Graeme Currie,Carol L. Brosgart,Joerg Petersen +13 more
TL;DR: Combined therapy with peg‐IFN and ADV led to marked decreases in serum HBV‐DNA and intrahepatic cccDNA, which was significantly correlated with reduced HBsAg, suggesting the involvement of cytolytic mechanisms.
Journal ArticleDOI
Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein.
Joerg Petersen,Maura Dandri,Walter Mier,Marc Lütgehetmann,Tassilo Volz,Fritz von Weizsäcker,Uwe Haberkorn,Lutz Fischer,Joerg M. Pollok,Berit Erbes,Stefan Seitz,Stephan Urban +11 more
TL;DR: Inhibition of hepadnavirus entry constitutes a therapeutic approach to prevent primary HBV infection, such as after liver transplantation, and might also restrain virus spread in chronically infected patients.